Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from BioInvent International AB ( (SE:BINV) ) is now available.
BioInvent International AB will seek to deepen engagement with global investors and industry partners in January 2026 through participation in several high-profile investor and healthcare conferences in San Francisco and Stockholm. The company’s management will hold one-on-one meetings at the J.P. Morgan 2026 Healthcare Conference and the LifeSci Partners Corporate Access Event, join a Swedish-focused panel at the J.P. Morgan networking breakfast, and present with a Q&A session at the Redeye Fight Cancer event, moves that underscore its efforts to raise visibility around its cancer immunotherapy pipeline and to support potential partnering and financing opportunities.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish clinical-stage biotech company specializing in the discovery and development of novel, first-in-class immune-modulatory antibodies for cancer therapy, targeting both hematological malignancies and solid tumors. Leveraging its proprietary F.I.R.S.T. technology platform, the company identifies antibody targets and corresponding antibodies, supporting its own immuno-oncology pipeline, licensing opportunities, and revenue-generating research collaborations and contract manufacturing for major pharmaceutical partners.
Average Trading Volume: 93,815
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.84B
Find detailed analytics on BINV stock on TipRanks’ Stock Analysis page.